Latest news with #Eleva
Yahoo
07-07-2025
- Health
- Yahoo
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
First-in-human administration of CPV-104 marks a major step in drug development for the company's lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company's Factor H (CPV-104) program in C3-Glomerulopathy (C3G). In the first part of the clinical study, Eleva is investigating single-ascending doses of CPV-104 in healthy volunteers. 'Today's news marks our second proprietary program advancing into clinical trials, which is a great achievement from an organizational standpoint,' commented Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. 'Our Factor H biological therapy platform continues to evolve, gaining visibility among clinicians and potential partners alike. We will continue to add value to this program in C3G as our initial focus, dry AMD as a second indication, and potentially several others down the road, while creating the best infrastructure for its successful clinical development.' 'We are thrilled to advance our Factor H molecule into a first-in-human study to evaluate the safety and tolerability and pharmacokinetics for further clinical studies. I like to thank all team members at Eleva and our clinical partners for their continued efforts and commitment to meet this milestone,' commented Dr. Martin Bauer, Chief Medical Officer of Eleva. C3G represents a rare renal disease caused by the abnormal regulation of the complement system, particularly the alternative pathway of the complement cascade, a central part of the body's immune defense. Naturally occurring complement regulators such as Factor H offer a therapeutic approach to help restore balance within the complement system and have shown therapeutic potential in a range of indications. Preclinical data sets were recently published in Frontiers in Immunology and underscored Factor H (CPV-104)'s ability to act as a functional analogue of human Factor H, support normalization of serum C3 levels and lead to a rapid degradation of C3 deposits in the kidney. The program has received the Orphan Drug Designation in the European Union for C3G and is also being pursued by Eleva in dry AMD as a second indication. ABOUT ELEVAEleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva's disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that other platforms cannot achieve. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company's aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease. MEDIA CONTACTS Fabienne ZeitterDirector Marketingpr@ +49 761 470 99 0 Valency CommunicationsMario Brkuljmbrkulj@ +49 160 9352 9951 INVESTOR CONTACT Cohesion BureauGiovanni Ca' +33 7 84 67 07 27 Attachment 250707_Eleva_1st_Dosing_FactorH_ENG
Associated Press
07-07-2025
- Health
- Associated Press
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
First-in-human administration of CPV-104 marks a major step in drug development for the company's lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company's Factor H (CPV-104) program in C3-Glomerulopathy (C3G). In the first part of the clinical study, Eleva is investigating single-ascending doses of CPV-104 in healthy volunteers. 'Today's news marks our second proprietary program advancing into clinical trials, which is a great achievement from an organizational standpoint,' commented Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. 'Our Factor H biological therapy platform continues to evolve, gaining visibility among clinicians and potential partners alike. We will continue to add value to this program in C3G as our initial focus, dry AMD as a second indication, and potentially several others down the road, while creating the best infrastructure for its successful clinical development.' 'We are thrilled to advance our Factor H molecule into a first-in-human study to evaluate the safety and tolerability and pharmacokinetics for further clinical studies. I like to thank all team members at Eleva and our clinical partners for their continued efforts and commitment to meet this milestone,' commented Dr. Martin Bauer, Chief Medical Officer of Eleva. C3G represents a rare renal disease caused by the abnormal regulation of the complement system, particularly the alternative pathway of the complement cascade, a central part of the body's immune defense. Naturally occurring complement regulators such as Factor H offer a therapeutic approach to help restore balance within the complement system and have shown therapeutic potential in a range of indications. Preclinical data sets were recently published in Frontiers in Immunology and underscored Factor H (CPV-104)'s ability to act as a functional analogue of human Factor H, support normalization of serum C3 levels and lead to a rapid degradation of C3 deposits in the kidney. The program has received the Orphan Drug Designation in the European Union for C3G and is also being pursued by Eleva in dry AMD as a second indication. ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva's disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that other platforms cannot achieve. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company's aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease. MEDIA CONTACTS INVESTOR CONTACT Attachment
Business Upturn
13-05-2025
- Business
- Business Upturn
Eleva Appoints Donato Spota as Chief Financial Officer
By GlobeNewswire Published on May 13, 2025, 11:30 IST Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer. 'Eleva continues to strengthen its leadership team in line with the growing maturity of our proprietary development activities and steady progress in commercializing our technology platform. It is a pleasure to welcome Donato, whose proven experience in financial management of rapidly growing companies, makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,' commented Björn Cochlovius, Ph.D., Chief Executive Officer and Managing Director of Eleva. 'I also want to express my special thanks to Danielle Püschel for her commitment and leadership over the last 16 years at Eleva. The entire team is glad Danielle will continue her career with the company.' Mr. Spota is a senior executive with more than 25 years of international pharmaceutical industry experience. In his previous position as CFO of Hansa Biopharma, a Nasdaq Stockholm-listed biopharmaceutical company, he supported the progress of Hansa Biopharma's R&D pipeline and its transformation to a commercial-stage company by contributing to the corporate business and financial strategy and securing growth financing in excess of USD 200 million. Prior to joining Hansa Biopharma, Mr. Spota was CFO at Basilea Pharmaceutica AG, a Swiss-listed biopharmaceutical company. Mr. Spota held other senior financial leadership positions, including Global Head of Finance & Services and Head of Global Controlling at Basilea. Mr. Spota holds a degree in Information Technology and an in Business Administration from the HfWU University Nürtingen-Geislingen, Germany. Donato Spota added: 'Eleva is accelerating and expanding both of its core business activities in proprietary drug development and high-value product partnerships based on our transformative technology platform. I'm looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva's growth strategy for both strategic pillars of this exciting business.' ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company's aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva's transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential. MEDIA CONTACTS INVESTOR CONTACT Attachments 13MAY2025_Eleva_CFO_Appointment_ENG_FINAL Donato Spota Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
13-05-2025
- Business
- Yahoo
Eleva Appoints Donato Spota as Chief Financial Officer
Donato Spota Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer. 'Eleva continues to strengthen its leadership team in line with the growing maturity of our proprietary development activities and steady progress in commercializing our technology platform. It is a pleasure to welcome Donato, whose proven experience in financial management of rapidly growing companies, makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,' commented Björn Cochlovius, Ph.D., Chief Executive Officer and Managing Director of Eleva. 'I also want to express my special thanks to Danielle Püschel for her commitment and leadership over the last 16 years at Eleva. The entire team is glad Danielle will continue her career with the company.' Mr. Spota is a senior executive with more than 25 years of international pharmaceutical industry experience. In his previous position as CFO of Hansa Biopharma, a Nasdaq Stockholm-listed biopharmaceutical company, he supported the progress of Hansa Biopharma's R&D pipeline and its transformation to a commercial-stage company by contributing to the corporate business and financial strategy and securing growth financing in excess of USD 200 million. Prior to joining Hansa Biopharma, Mr. Spota was CFO at Basilea Pharmaceutica AG, a Swiss-listed biopharmaceutical company. Mr. Spota held other senior financial leadership positions, including Global Head of Finance & Services and Head of Global Controlling at Basilea. Mr. Spota holds a degree in Information Technology and an in Business Administration from the HfWU University Nürtingen-Geislingen, Germany. Donato Spota added: 'Eleva is accelerating and expanding both of its core business activities in proprietary drug development and high-value product partnerships based on our transformative technology platform. I'm looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva's growth strategy for both strategic pillars of this exciting business.' ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company's aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva's transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential. MEDIA CONTACTS Fabienne ZeitterDirector Marketingpr@ Phone: +49 761 470 99 0 Valency CommunicationsMario Brkuljmbrkulj@ +49 160 9352 9951 INVESTOR CONTACT Cohesion BureauGiovanni Ca' Phone: +33 7 84 67 07 27 Attachments 13MAY2025_Eleva_CFO_Appointment_ENG_FINAL Donato Spota
Yahoo
19-03-2025
- Yahoo
Man in court on seventh OWI charge
EAU CLAIRE — An Eleva man charged with his seventh OWI was in court Tuesday for a hearing in the case. Robert Smith, 54, faces charges of OWI-7 and driving with a prohibited alcohol concentration, seventh offense. The charges were filed in December. According to the criminal complaint, a state trooper was approached at a gas station by someone who was concerned about Smith's behavior. The trooper used his vehicle to box Smith in and spoke to him. Smith was off balance and, when asked for his license, handed over a debit or credit card. Smith said he had called his wife and told her he couldn't drive. While talking with the trooper he stopped to take a call on his cell phone from his wife. Smith failed field sobriety tests and blew a .278 on a breath test, almost three-and-a-half times the legal limit. A subsequent blood draw showed a level of .262. Under Wisconsin law anyone with three OWI convictions has a limit of .02. A seventh OWI is a Class F felony, with the potential for up to 12.5 years in prison. Fines can reach $25,000. Smith has not yet entered a plea.
